PURPOSE: Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standardized uptake value corrected for lean body mass (SULmax) on 18F-labeled fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) would predict pathologic complete response (pCR) to pertuzumab and trastuzumab (PT). PATIENTS AND METHODS: Patients with stage II or III, estrogen receptor-negative, HER2-positive breast cancer received four cycles of neoadjuvant PT. 18F-labeled fluorodeoxyglucose positron emission tomography-computed tomography was performed at baseline and 15 days after PT initiation (C1D15). Eighty evaluable patients were required to test the null hypothesis that the area under the curve of percent change in SULmax by C1D15 predicting pCR is ≤ 0.65, with a one-sided type I error rate of 10%. RESULTS: Eighty-eight women were enrolled (83 evaluable), and 85% (75 of 88) completed all four cycles of PT. pCR after PT alone was 22%. Receiver operator characteristic analysis of percent change in SULmax by C1D15 yielded an area under the curve of 0.72 (80% CI, 0.64 to 0.80; one-sided P = .12), which did not reject the null hypothesis. However, between patients who obtained pCR and who did not, a significant difference in median percent reduction in SULmax by C1D15 was observed (63.8% v 41.8%; P = .004) and SULmax reduction ≥ 40% was more prevalent (83% v 52%; P = .03; positive predictive value, 31%). Participants not obtaining a 40% reduction in SULmax by C1D15 were unlikely to obtain pCR (negative predictive value, 91%). CONCLUSION: Although the primary objective was not met, early changes in SULmax predict response to PT in estrogen receptor-negative and HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate tailoring of therapy in this setting.
PURPOSE: Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standardized uptake value corrected for lean body mass (SULmax) on 18F-labeled fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) would predict pathologic complete response (pCR) to pertuzumab and trastuzumab (PT). PATIENTS AND METHODS: Patients with stage II or III, estrogen receptor-negative, HER2-positive breast cancer received four cycles of neoadjuvant PT. 18F-labeled fluorodeoxyglucose positron emission tomography-computed tomography was performed at baseline and 15 days after PT initiation (C1D15). Eighty evaluable patients were required to test the null hypothesis that the area under the curve of percent change in SULmax by C1D15 predicting pCR is ≤ 0.65, with a one-sided type I error rate of 10%. RESULTS: Eighty-eight women were enrolled (83 evaluable), and 85% (75 of 88) completed all four cycles of PT. pCR after PT alone was 22%. Receiver operator characteristic analysis of percent change in SULmax by C1D15 yielded an area under the curve of 0.72 (80% CI, 0.64 to 0.80; one-sided P = .12), which did not reject the null hypothesis. However, between patients who obtained pCR and who did not, a significant difference in median percent reduction in SULmax by C1D15 was observed (63.8% v 41.8%; P = .004) and SULmax reduction ≥ 40% was more prevalent (83% v 52%; P = .03; positive predictive value, 31%). Participants not obtaining a 40% reduction in SULmax by C1D15 were unlikely to obtain pCR (negative predictive value, 91%). CONCLUSION: Although the primary objective was not met, early changes in SULmax predict response to PT in estrogen receptor-negative and HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate tailoring of therapy in this setting.
Authors: Michael M Graham; Richard L Wahl; John M Hoffman; Jeffrey T Yap; John J Sunderland; Ronald Boellaard; Eric S Perlman; Paul E Kinahan; Paul E Christian; Otto S Hoekstra; Gary S Dorfman Journal: J Nucl Med Date: 2015-04-16 Impact factor: 10.057
Authors: Andreas Engert; Heinz Haverkamp; Carsten Kobe; Jana Markova; Christoph Renner; Antony Ho; Josée Zijlstra; Zdenek Král; Michael Fuchs; Michael Hallek; Lothar Kanz; Hartmut Döhner; Bernd Dörken; Nicole Engel; Max Topp; Susanne Klutmann; Holger Amthauer; Andreas Bockisch; Regine Kluge; Clemens Kratochwil; Otmar Schober; Richard Greil; Reinhard Andreesen; Michael Kneba; Michael Pfreundschuh; Harald Stein; Hans Theodor Eich; Rolf-Peter Müller; Markus Dietlein; Peter Borchmann; Volker Diehl Journal: Lancet Date: 2012-04-04 Impact factor: 79.321
Authors: Antonio Llombart-Cussac; Javier Cortés; Laia Paré; Patricia Galván; Begoña Bermejo; Noelia Martínez; Maria Vidal; Sònia Pernas; Rafael López; Montserrat Muñoz; Paolo Nuciforo; Serafín Morales; Mafalda Oliveira; Lorena de la Peña; Alexandra Peláez; Aleix Prat Journal: Lancet Oncol Date: 2017-02-24 Impact factor: 41.316
Authors: Roisin M Connolly; Jeffrey P Leal; Lilja Solnes; Chiung-Yu Huang; Ashley Carpenter; Katy Gaffney; Vandana Abramson; Lisa A Carey; Minetta C Liu; Mothaffar Rimawi; Jennifer Specht; Anna Maria Storniolo; Vicente Valero; Christos Vaklavas; Ian E Krop; Eric P Winer; Melissa Camp; Robert S Miller; Antonio C Wolff; Ashley Cimino-Mathews; Ben H Park; Richard L Wahl; Vered Stearns Journal: J Clin Oncol Date: 2019-02-05 Impact factor: 44.544
Authors: U A Nitz; O Gluz; M Christgen; E-M Grischke; D Augustin; S Kuemmel; M Braun; J Potenberg; A Kohls; K Krauss; A Stefek; C Schumacher; H Forstbauer; T Reimer; H Fischer; C Liedtke; R Wuerstlein; J Schumacher; R Kates; H Kreipe; N Harbeck Journal: Ann Oncol Date: 2017-11-01 Impact factor: 32.976
Authors: Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Lisi M Dredze; Michael Friger; Samuel Ariad; Michael Koretz; Bertha Delgado; Ruthy Shaco-Levy; Margarita Tokar; Michael Bayme; Ravit Agassi; Maia Rosenthal; Victor Dyomin; Olga Belochitski; Shai Libson; Tamar Mizrahi; David B Geffen Journal: Breast Cancer Res Treat Date: 2022-04-22 Impact factor: 4.872